|Systematic (IUPAC) name|
|Molar mass||373.44 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Bunazosin (INN) is an alpha 1 antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.
|40px||This antihypertensive-related article is a stub. You can help ssf by expanding it.|